Episode 62
Biotech Hangout
00:00
Secondary Financing Activity in the Market
Otello: I think one area that everyone agrees is that out of pocket costs for patients really need to get down. There's been quite a few examples of that over the last few weeks, including some very, very sizable raises in the secondary market. So I think there's a very large number of specialists where we look into deploy actively into what they will see as interesting clinical stories. AndI wouldn't necessarily stretch that into a trend that will translate necessarily to IPOs being super back in fashion or whatever the expression is.
Transcript
Play full episode
